VIGILA: COMPREHENSIVE FAMILY OF DEFIBRILLATION LEADS

VIGILA: COMPREHENSIVE FAMILY OF DEFIBRILLATION LEADS

LEAD YOUR PATIENTS TO INDIVIDUALIZED THERAPY
 
VIGILA defibrillation leads’ performance and safety, combined with Sorin Group’s ICD unique algorithms, provide reliable and individualized therapies for your patients.1

  • 7.8F isodiametric lead body – fits through an 8F introducer
  • 65cm lead – active or passive fixation
  • Single or dual shock coils – 18cm from tip to SVC coil (dual coil)
  • Steroid reservoir – dexamethasone acetate
  • Dedicated bipolar sensing

SAFETY BY DESIGN AND PROVEN DURABILITY2
 
Engineered with safety in mind from body to tip, the VIGILA lead family is built to provide the highest level of quality and lasting performance.


 
Convex shock coil
 
VIGILA leads are engineered to minimize tissue in-growth:3

  • Convex shock coils with silicone backfill provide a smooth surface
  • VIGILA leads’ convex shock coils are engineered with a reduced interstitial space between the coil turns. This architecture is designed to effectively prevent the formation of tissue

 

Soft atraumatic tip
 
When pressure is applied to the lead, the soft atraumatic tip changes form.
The soft tip helps to reduce:

  • Tissue trauma
  • Risk of perforations

 

Symmetrical silicone lead body for long-term durability

  • Symmetrical architecture for even distribution and resistance to external stress
  • Thick 0.28mm outer silicone insulation for enhanced prevention of abrasion

 

PREDICTABLE HANDLING AND OUTCOMES

VIGILA leads offer simple handling and maneuverability through their distinctive design, combining:

  • Convex shock coils with silicone backfill
  • Flexible distal portion of the lead
  • Symmetrical silicone lead body

 
EFFECTIVE ELECTRICAL PERFORMANCE4

Iridium fractal coating technology provides:

  • Excellent sensing
  • Low acute and stable chronic thresholds
  • High impedance for prolonged battery life
  • Efficient post-shock sensing recovery

True bipolar sensing for improved signal-to-noise ratio
 

 
References:
1. Sorin Group, data on fi le
2. BIOTRONIK data – Product Performance Report, July 2011
3. Haqqani HM, Mond HG. The implantable cardioverter-defi brillator lead: principles, progress and promises
PACE. 2009; 32: 1336–1353
4. BIOTRONIK data – Linox Master Study, 2007

Not available for distribution or sales in the USA

This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative
Up